Neurocrine Biosciences financials
$138.35−1.49%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $959.0M | $814.5M | $805.5M | $794.9M | $687.5M | $572.6M | $627.7M | $622.1M | $590.2M | $515.3M | $515.2M | $498.8M |
| Gross profit | $935.8M | $800.7M | $787.9M | $780.9M | $677.2M | $563.4M | $618.4M | $614.1M | $581.0M | $507.8M | $506.7M | $487.6M |
| Gross margin | 97.6% | 98.3% | 97.8% | 98.2% | 98.5% | 98.4% | 98.5% | 98.7% | 98.4% | 98.5% | 98.4% | 97.8% |
| Operating income | $151.5M | $164.8M | $210.9M | $239.0M | $145.6M | $23.6M | $142.0M | $183.8M | $145.4M | $99.3M | $150.3M | $141.2M |
| Net income | $144.4M | $197.9M | $153.7M | $209.5M | $107.5M | $7.9M | $103.1M | $129.8M | $65.0M | $43.4M | $147.7M | $83.1M |
| Net margin | 15.1% | 24.3% | 19.1% | 26.4% | 15.6% | 1.4% | 16.4% | 20.9% | 11.0% | 8.4% | 28.7% | 16.7% |
| Diluted EPS | $1.39 | $1.91 | $1.48 | $2.04 | $1.06 | $0.08 | $1.00 | $1.24 | $0.63 | $0.42 | $1.40 | $0.82 |
| EBITDA | $161.3M | $193.3M | $235.4M | $247.0M | $150.9M | $31.3M | $152.1M | $191.3M | $155.2M | $111.5M | $150.3M | $146.7M |
| Operating cash flow | $136.4M | $145.8M | $388.4M | $227.5M | $102.0M | $64.8M | $242.5M | $158.0M | $64.6M | $130.3M | $123.5M | $212.0M |
| Free cash flow | $128.6M | $136.7M | $386.0M | $214.3M | $89.5M | $54.1M | $235.2M | $149.9M | $53.0M | $119.1M | $118.1M | $204.4M |
| Diluted shares | 104.2M | 103.4M | 104.0M | 102.5M | 101.0M | 102.5M | 103.0M | 104.3M | 103.9M | 103.6M | 105.6M | 101.1M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $332.4M | $266.5M | $713.0M | $340.2M | $264.0M | $194.1M |
| Short-term investments | $57.4M | $1.05B | $767.4M | $774.6M | $711.6M | $749.4M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $5.36B | $4.91B | $4.63B | $4.27B | $3.89B | $3.69B |
| Total liabilities | $1.67B | $1.50B | $1.38B | $1.26B | $1.20B | $1.15B |
| Shareholders' equity | $3.69B | $3.41B | $3.25B | $3.00B | $2.69B | $2.54B |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology